Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dezocine Pretreatment for Pain Relief in Acne Scar Laser Treatment
NCT05861063Phase 4
Key facts
- Status
- Unknown
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Countries
- 1
- Sponsor
- Xijing Hospital
- Modality
- Orthosteric Ligands
- Drugs
- dezocine
- Conditions
- procedural pain
01
Overview
Phase 4, randomised trial of dezocine in procedural pain (3 arms), sponsored by Xijing Hospital. Primary endpoints: Visual Analog Score for Pain at 24 hours, Hemodynamic parameters at 24 hours and 2 more. Status: unknown.
02
Design
3 arms- Study design
- Randomized
Control Group
Placebo (Normal Saline) + Laser
Dezocine Low Dose
Low dose Dezocine + Laser
Dezocine High Dose
High dose Dezocine + Laser
03
Who it enrols
Adult patients aged 18-60 with atrophic acne scars planning to undergo ultra-pulsed CO2 lattice laser therapy. Excludes patients with severe heart, lung, liver, or kidney diseases, psychosis, pregnancy, communication disorders, history of hypertension >160/100mmHg, sleep apnea, increased intracranial pressure, alcoholism, hypotension, hypothyroidism, acute asthma, or epilepsy.
04
Endpoints
Primary
Visual Analog Score for Pain
Hemodynamic parameters
Heart rate (HR)
oxygen saturation (SpO2)
Secondary
Occurrence of Adverse Reactions
Beyond the preview
Go deeper on NCT05861063.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861063.